Particulate Matter Definition & Meaning | Manufacturing Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Particulate Matter

Manufacturing Term

Particulate matter (PM) refers to a mixture of solid particles and liquid droplets in the air, varying in size from a few nanometers to tens of micrometers. Sources of PM include natural sources such as dust and forest fires, as well as human activities like transportation, power generation, and industrial processes.

In the manufacturing industry, PM can be generated by a variety of processes such as grinding, cutting, sanding, and welding. Exposure to high levels of PM can have adverse effects on human health, including respiratory and cardiovascular diseases.

To mitigate the impacts of PM on worker health and safety, various dust control measures can be implemented. These include designing processes to minimize dust generation, using wet methods to suppress dust, installing ventilation systems to capture and remove dust from the air, and providing personal protective equipment such as respirators.

Additionally, PM can be used in manufacturing processes. For example, PM can be used to create metal powders for 3D printing or as a component in paint and coatings to improve durability and provide texture. PM can also be used as a catalyst in chemical reactions or as a carrier for delivering drugs and other substances.

Overall, the management of PM in manufacturing is crucial for protecting worker health and safety as well as ensuring high-quality product output.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P